WhayneT.F.Jr.. Is there a problem with ezetimibe or just ENHANCEd hype?Angiology.2008 Sep 15 [Epub ahead of print].
2.
PedoneC., CarboninP., KasteleinJ.J.ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.N Engl J Med.2008; 358: 1431–1443.
3.
JansenA.C., van Aalst-CohenE.S., TanckM.W.The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.J Intern Med.2004; 256: 482–490.
4.
de Sauvage NoltingP.R., DefescheJ.C., BuirmaR.J., HuttenB.A., LansbergP.J., KasteleinJ.J.Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia.J Intern Med. 2003; 253: 161–168.
5.
SugrueD.D., TraynerI., ThompsonG.R.Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia.Br Heart J.1985; 53: 265–268.
6.
JansenA.C., van Aalst-CohenE.S., TanckM.W., Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia.Arterioscler Thromb Vasc Biol.2005; 25: 1475–1481.
7.
RossebøA.B., PedersenT.R., BomanK.for the SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.N Engl J Med.2008; 359: 1343–1356.
8.
GoldsteinM.R., MascitelliL., PezzettaF.The double-edged sword of statin immunomodulation.Int J Cardiol.2008 May 15 [Epub ahead of print].
9.
ShepherdJ., BlauwG.J., MurphyM.B., and the PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Lancet.2002; 360: 1623–1630.
10.
BradfordP.G., AwadA.B.Phytosterols as anticancer compounds.Mol Nutr Food Res.2007; 51: 161–170.
11.
RavnskovU.Re: the association between statins and cancer incidence in a veterans population.J Natl Cancer Inst.2008; 100: 972–973.
